Veracyte, Inc. (NASDAQ:VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier in assisting physicians make more informed treatment decisions for their patients with prostate cancer.
What To Know: The data was revealed at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting and suggests that the Decipher Prostate test can more precisely categorize the risk of patients with clinically high-risk disease to aid in reaching the appropriate treatment.
“The findings presented at ASTRO 2023 add to the large body of evidence, which now includes 12 phase 3 randomized trials, demonstrating the Decipher Prostate classifier’s performance as a tool to help guide therapeutic decisions in prostate cancer,” said Elai Davicioni, Veracyte’s medical director for Urology. “Furthermore, they reinforce that the substantial level of evidence supporting the Decipher Prostate test can help guide its selection and utilization for patients with prostate cancer.”
Related Link: Why Accolade Stock Is Falling After-Hours
VCYT Price Action: Shares of VCYT were up 0.19% at $21.52 in the after-hours session at the time of publication, according to Benzinga Pro.
Image by Adam Novak from Pixabay
